March 8 (SeeNews) - North Macedonia's pharmaceuticals producer Replek [MSE:REPL] made a consolidated net profit of 81.9 million denars ($1.4 million/1.3 million euro) last year, down 39% on an annual comparison basis.
Total operating revenues went up 9% year-on-year to 1.4 billion denars in 2022, while total operating costs were 9% higher at 1.2 billion denars, Replek said in an annual financial statement last week.
The company's amortisation and depreciation costs soared to 67.8 million denars in the year under review from 12.8 million denars in 2021.
Replek's shares changed hands on the Macedonian Stock Exchange (MSE) at an average price of 81,998 denars on Tuesday, latest bourse data shows.
(1 euro = 61.06 denars)